TP53 and neoplasm: It seems that apart from the known dysregulation of homologous recombination deficiency (HRD) and TP53, both of which play an important role in tumour initiation of HGSOC [9, 10], additional molecular mechanisms, for example, the upregulation of a therapy resistance-related drug efflux pump (MDR1) become important for tumour preservation after primary chemotherapy [8].